OssDsign extends the Catalyst portfolio and launches new product for additional surgical procedures

Uppsala, 3 November 2022. OssDsign AB (publ.) announces today that the company is launching a new size of OssDsign Catalyst. The additional volume option of 1 cubic centimetre (cc) completes the existing product range of 10, 5 and 2,5 ccs, and broadens the access to new procedures in both cervical spine and smaller extremities. The product is expected to launch in the first quarter of 2023.

 The addition of the 1cc option completes the size range of OssDsign Catalyst, giving the company competitive strength in hospital approval processes and allowing for deeper usage in already approved hospitals. Equally important, the 1cc size allows the company to target Ambulatory Surgery Centers (ASCs). These centers engage a large number of surgeons from different hospitals, thereby increasing product awareness among a broader surgeon population.

“We are very happy to extend our offering and further increase our commercial opportunity, as our new smaller size of OssDsign Catalyst gives access to additional procedures. It also means we can now offer a complete and more competitive size range to both existing users and new potential hospitals,” says Morten Henneveld, CEO.

OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue in the body.

Tags: